A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers

NCT05718921 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis
Psoriasis

Interventions

DRUG: YR001 Dose A on low body surface area
DRUG: YR001 Dose A on middle body surface area
DRUG: YR001 Dose A on high body surface area
DRUG: YR001 Dose B on low body surface area
DRUG: YR001 Dose B on middle body surface area
DRUG: YR001 Dose B on high body surface area
DRUG: Placebo on low body surface area
DRUG: Placebo on middle body surface area
DRUG: Placebo on high body surface area
DRUG: YR001 Dose A on high body surface area twice daily
DRUG: YR001 Dose B on high body surface area twice daily
DRUG: Placebo on high body surface area twice daily

Sponsor

Hangzhou Yirui Pharmaceutical Technology Co., Ltd